Weilun Lo

Array ( [id] => 18294531 [patent_doc_number] => 20230104217 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-06 [patent_title] => FUSION PROTEIN COMPRISING IL-2 PROTEIN AND CD80 PROTEIN, AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/948894 [patent_app_country] => US [patent_app_date] => 2022-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25680 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 103 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17948894 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20129200 [patent_doc_number] => 12371502 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-29 [patent_title] => Antibodies directed against CD127 [patent_app_type] => utility [patent_app_number] => 17/941885 [patent_app_country] => US [patent_app_date] => 2022-09-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 28 [patent_no_of_words] => 30731 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 158 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17941885 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18582878 [patent_doc_number] => 20230265135 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-24 [patent_title] => METHODS AND COMPOSITIONS FOR TREATING AND/OR PREVENTING A DISEASE OR DISORDER ASSOCIATED WITH ABNORMAL LEVEL AND/OR ACTIVITY OF THE IFP35 FAMILY OF PROTEINS [patent_app_type] => utility [patent_app_number] => 17/930635 [patent_app_country] => US [patent_app_date] => 2022-09-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36110 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17930635 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20157015 [patent_doc_number] => 12383613 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-08-12 [patent_title] => Recombinant antigen and method of making the same, isolated polynucleotide of porcine reproductive and respiratory syndrome virus (PRRSV) and immunogenic composition including the same [patent_app_type] => utility [patent_app_number] => 17/930168 [patent_app_country] => US [patent_app_date] => 2022-09-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 13 [patent_no_of_words] => 0 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17930168 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18537538 [patent_doc_number] => 20230242636 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-03 [patent_title] => MONOCLONAL ANTIBODIES TARGETED TO HUMAN TAXILIN ALPHA AND METHODS FOR USE OF SAME [patent_app_type] => utility [patent_app_number] => 17/930028 [patent_app_country] => US [patent_app_date] => 2022-09-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4046 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17930028 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18273724 [patent_doc_number] => 11612645 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-03-28 [patent_title] => IL-15-based fusions to IL-12 and IL-18 [patent_app_type] => utility [patent_app_number] => 17/820980 [patent_app_country] => US [patent_app_date] => 2022-08-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 32 [patent_no_of_words] => 30057 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 88 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17820980 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18522958 [patent_doc_number] => 20230233608 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-27 [patent_title] => REGULATED BIOCIRCUIT SYSTEMS [patent_app_type] => utility [patent_app_number] => 17/888808 [patent_app_country] => US [patent_app_date] => 2022-08-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 70310 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 93 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17888808 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18037576 [patent_doc_number] => 20220381792 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-01 [patent_title] => METHOD FOR DIAGNOSING AND TREATING FIBROMYALGIA [patent_app_type] => utility [patent_app_number] => 17/885829 [patent_app_country] => US [patent_app_date] => 2022-08-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7040 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -46 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17885829 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18536102 [patent_doc_number] => 20230241189 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-03 [patent_title] => Compositions and Methods for Treating Granulomatosis with Polyangiitis [patent_app_type] => utility [patent_app_number] => 17/818934 [patent_app_country] => US [patent_app_date] => 2022-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19738 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17818934 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18036237 [patent_doc_number] => 20220380452 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-01 [patent_title] => BIOPHARMACEUTICAL COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 17/881988 [patent_app_country] => US [patent_app_date] => 2022-08-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41010 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 103 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17881988 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18057984 [patent_doc_number] => 20220389070 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-08 [patent_title] => FUSION PROTEIN COMPRISING IL-2 PROTEIN AND CD80 PROTEIN, AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/878703 [patent_app_country] => US [patent_app_date] => 2022-08-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21207 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 108 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17878703 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19916202 [patent_doc_number] => 12291555 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-05-06 [patent_title] => Fusion protein comprising IL-2 protein and CD80 protein, and use thereof [patent_app_type] => utility [patent_app_number] => 17/878664 [patent_app_country] => US [patent_app_date] => 2022-08-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 63 [patent_figures_cnt] => 90 [patent_no_of_words] => 17150 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17878664 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18326308 [patent_doc_number] => 20230124436 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-20 [patent_title] => QTY FC FUSION RECEPTOR PROTEINS [patent_app_type] => utility [patent_app_number] => 17/877091 [patent_app_country] => US [patent_app_date] => 2022-07-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13585 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17877091 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17980379 [patent_doc_number] => 20220346415 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-03 [patent_title] => ANTIBODY-CYTOKINE ENGRAFTED PROTEINS AND METHODS OF USE FOR IMMUNE RELATED DISORDERS [patent_app_type] => utility [patent_app_number] => 17/813232 [patent_app_country] => US [patent_app_date] => 2022-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28992 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17813232 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18195657 [patent_doc_number] => 20230049176 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-16 [patent_title] => METHODS TO DECREASE IMPURITIES FROM RECOMBINANT PROTEIN MANUFACTURING PROCESSES [patent_app_type] => utility [patent_app_number] => 17/812145 [patent_app_country] => US [patent_app_date] => 2022-07-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11439 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17812145 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19651293 [patent_doc_number] => 12173062 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-24 [patent_title] => Modified TNF-a antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 17/861178 [patent_app_country] => US [patent_app_date] => 2022-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 36 [patent_no_of_words] => 43435 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 77 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17861178 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18150097 [patent_doc_number] => 20230023954 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-26 [patent_title] => MULTI-FUNCTIONAL AND MULTI-VALENT INTERLEUKIN-TGF-BETA RECEPTOR FUSION POLYPEPTIDES [patent_app_type] => utility [patent_app_number] => 17/810128 [patent_app_country] => US [patent_app_date] => 2022-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26098 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17810128 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20129203 [patent_doc_number] => 12371505 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-29 [patent_title] => Anti-BCMA heavy chain-only antibodies [patent_app_type] => utility [patent_app_number] => 17/853794 [patent_app_country] => US [patent_app_date] => 2022-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 7 [patent_no_of_words] => 4451 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17853794 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20157004 [patent_doc_number] => 12383602 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-08-12 [patent_title] => HLA-B57 open conformers [patent_app_type] => utility [patent_app_number] => 17/849643 [patent_app_country] => US [patent_app_date] => 2022-06-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 17 [patent_no_of_words] => 7604 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17849643 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18117551 [patent_doc_number] => 11548932 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-10 [patent_title] => Anti-VEGF protein compositions and methods for producing the same [patent_app_type] => utility [patent_app_number] => 17/841349 [patent_app_country] => US [patent_app_date] => 2022-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 60 [patent_figures_cnt] => 86 [patent_no_of_words] => 67417 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17841349 [rel_patent_id] =>[rel_patent_doc_number] =>)